Communiqués 3SBio Inc. BOERSE MUENCHEN

Actions

83B

KYG8875G1029

Temps réel BOERSE MUENCHEN Autres places de cotation 14:13:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
0,785 ^EUR	0,00%		+3,97%	-7,65%

25/06	3Sbio Inc. déclare un dividende final pour l'exercice clos le 31 décembre 2023, payable le 5 août 2024	CI
25/06	3Sbio Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	25/08/23	PR
3SBio : 2023 Interim Results Presentation	24/08/23	PU
3SBio : 2022 ESG Report	28/04/23	PU
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%	22/03/23	PR
3SBio : 2022 Interim Results Presentation	24/08/22	PU
3SBio : 1530.HK) _ Prospectus	24/06/22	PU
3SBio : 2021 ESG Report	25/05/22	PU
3SBio : 2021Annual Report	29/04/22	PU
3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses	30/03/22	PU
3SBIO : 2021Annual Results	29/03/22	PU
3SBio : Documents on Display	21/12/21	PU
3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development	26/08/21	PU
3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth	30/03/21	PU
3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020	26/02/21	PU
3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration	14/12/20	PU
3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212	23/11/20	PR
3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China	14/09/20	PU
3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA	14/09/20	PU
3SBio : MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry	01/09/20	PU
3SBio : WITHDRAWAL OF LISTING OF THE ZERO COUPON CONVERTIBLE BONDS DUE 2022	28/08/20	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués 3SBio Inc. BOERSE MUENCHEN

Actions

83B

KYG8875G1029

Communiqués

Filtres